Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

NCT00753896 · Completed

Last updated 2026-05-28

This clinical trial tested the safety of a weekly injectable diabetes medication called exenatide in adults with type 2 diabetes who were already taking either a thiazolidinedione alone or combined with metformin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 134 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-10 · est. completion 2009-11

Where 26 sites · Canada, Mexico, Romania, South Africa, United States

What this study is testing ClinicalTrials.gov NCT00753896 ↗

Description as written by the study sponsor.

This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.

Treatments tested

exenatide Drug

subcutaneous injection, 2.0mcg, once weekly

Main thing measured	Percentage of Patients Experiencing Adverse Events
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00753896 ↗